Sanofi disclosed positive Phase 2 results for AlphaMedix, an alpha-emitting targeted radioligand therapy (developed with Orano Med/RadioMedix) for gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). In a 61‑patient study that included patients pretreated with beta-emitter Lutathera, AlphaMedix met primary endpoints for overall response rate and safety; Sanofi said secondary endpoints also showed benefit though full data will be presented at ESMO. The Phase 2 success validates the 212Pb lead‑212 platform for delivering high‑potency alpha radiation to somatostatin-receptor–expressing tumors and supports regulatory discussions, according to Sanofi. The readout also vindicates Sanofi’s sizable upfront investment to in-license the program and advances the field of alpha radiopharmaceuticals as competition intensifies among targeted radiotherapies.